Tag: Oncology

Clinical Data Healthcare & Pharmaceuticals News Oncology

MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan

Merck MSD

The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, 2026, alongside more than 90 additional abstracts.

Business Healthcare & Pharmaceuticals News Research

Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement

Merck MSD

Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.